Disease: Refractory Classic Hodgkin Lymphoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4524856
Disease: Refractory Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma 		0.010 Biomarker disease BEFREE As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda<sup>®</sup>) to submit evidence of its clinical and cost effectiveness for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (RRcHL) who did not respond to treatment with brentuximab vedotin. 30895564 2019